T Cell News and Research

Latest T Cell News and Research

Beike exits stem cell joint venture with SiriCell

Shenzhen Beike Biotechnology Co. Ltd. ("Beike") and SiriCell Technologies, Inc. announced that they are ending their partnership in "Beike Holdings Limited", a joint venture formed by the two companies in 2008. Going forward, Beike will exit the joint venture, and all current and future Beike Holdings-initiated business activities will operate exclusively under the SiriCell brand. Beike Holdings was established to expand the availability of Beike's stem cell products outside of China through collaborative hospital partnerships and new international subsidiaries.

8 Dec 2010

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Case Western Reserve University School of Medicine faculty members are reaping the rewards of funding from the National Institutes of Health, in the form of grants and contracts. The funding totals more than $6.4 million for four different research endeavors.

8 Dec 2010

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma.

8 Dec 2010

New technique may help develop novel treatments for brain diseases

Scientists have created a way to isolate neural stem cells - cells that give rise to all the cell types of the brain - from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.

8 Dec 2010

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. Data were presented from the podium at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

8 Dec 2010

GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.

8 Dec 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Cephalon, Inc. and Mesoblast Limited, today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

8 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine's Sue and Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world's first clinical trial using human neural stem cells to treat spinal cord injury.

8 Dec 2010

NIH awards Scripps Research $2.35M to study new treatment for obesity

The Scripps Research Institute has been awarded a $2.35 million grant from the National Institutes of Health to study a new way of treating obesity as part of a national consortium with the Dana-Farber Cancer Institute.

8 Dec 2010

Mobile phones use during pregnancy linked to behavioural problems in kids: Study

A new study finds that pregnant mums who regularly use mobile phones may be more likely to have children with behavioral problems, especially if these kids themselves start using mobile phones in their first seven years.

7 Dec 2010

Fluxion Biosciences announces launch of new BioFlux 1000Z system for live cell imaging

Fluxion Biosciences, Inc. announced that the new BioFlux 1000Z system for live cell imaging will be launched at the 50th American Society for Cell Biology Annual Meeting to be held December 11-15, 2010 in Philadelphia, PA. The BioFlux 1000Z is the latest addition to the BioFlux product family of instruments for cellular analysis under controlled shear flow.

From Fluxion Biosciences 7 Dec 2010

MP receives FDA IND approval for clinical trial with HTLV-I/II ELISA 4.0 and HTLV Blot.2.4

MP Biomedicals LLC announced today that it has received approval of its investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to start pivotal clinical trials in the USA with the MP Diagnostics™ HTLV-I/II ELISA 4.0 and HTLV Blot.2.4. Studies will be conducted within the American Red Cross, the California Department of Public Health, and LABS, Inc. The company is working closely with the principal investigator of the American Red Cross sites, Dr. Susan Stramer, Executive Scientific Officer.

From MP Biomedicals, LLC 7 Dec 2010

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Abbott and Bristol-Myers Squibb Company today announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone.

7 Dec 2010

$Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL$

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive data from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of ALCL. The data were presented today during an oral session at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

7 Dec 2010

FEI launches Magellan extreme resolution scanning electron microscope for life science imaging

FEI Company, a leading instrumentation company providing electron microscope systems for applications in research and industry, today announced the Magellan™ extreme resolution scanning electron microscope (SEM) optimized specifically for life science imaging. The first of its kind, the Magellan SEM enables life science researchers and cell biologists to actually view the entire organization of a cell in its natural, fully-hydrated state.

7 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

$Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010$

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

EntreMed, Inc., today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology Annual Meeting being held December 4-7 in Orlando, Florida.

7 Dec 2010

First Edition: December 7, 2010

In today's headlines, Senate leaders appear to be nearing a one-year deal on Medicare's physician pay problem.

7 Dec 2010

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that consolidation treatment with fractionated yttrium-90 (Y-90) labeled epratuzumab, after induction therapy with rituximab and CHOP (R-CHOP) chemotherapy, improved remission status of adult patients with diffuse large B-cell lymphoma (DLBCL), a form of aggressive lymphoma.

7 Dec 2010

T Cell News and Research

Latest T Cell News and Research

Beike exits stem cell joint venture with SiriCell

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Immunomedics reports CD22 antibody produced significant anti-tumor response

New technique may help develop novel treatments for brain diseases

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Researchers synthesize wound-healing peptides

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

NIH awards Scripps Research $2.35M to study new treatment for obesity

Mobile phones use during pregnancy linked to behavioural problems in kids: Study

Fluxion Biosciences announces launch of new BioFlux 1000Z system for live cell imaging

MP receives FDA IND approval for clinical trial with HTLV-I/II ELISA 4.0 and HTLV Blot.2.4

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

FEI launches Magellan extreme resolution scanning electron microscope for life science imaging

John Theurer Cancer Center presents research findings at ASH meeting

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

First Edition: December 7, 2010

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Immunology eBook

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Data management challenges in scientific research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Data management challenges in scientific research

Newsletters you may be interested in